Pooled analysis from these studies showed higher total AEs among adult ITP patients who received SYK and/or BTK inhibitors than those who received placebo (RR 1.14; 95%CI: 1.06 – 1.24, p=0.0006, I2 = 0%, random-effect model) (Figure 3A) (Table 3). This evidence concerns the gene BTK and autoimmune thrombocytopenic purpura.